Royal London Asset Management’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Royal London Asset Management’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$17.1K	Buy	+14,700	New	+$1.78M	0.03%	452

Other funds holding SLXP

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal London Asset Management's SLXP Position: Q4 2014 in Review

Royal London Asset Management opened a new position in SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q4 2014: 14,700 shares worth $17.1K. The stake represents 0.03% of the portfolio and ranks #452 among its holdings.

346 funds tracked by Wall St. Rank hold SLXP as of Q4 2014.

Royal London Asset Management held 14,700 shares of SALIX PHARMACEUTICALS LTD DEL worth $17.1K as of Q4 2014.
SALIX PHARMACEUTICALS LTD DEL was a new Royal London Asset Management position in Q4 2014.
SALIX PHARMACEUTICALS LTD DEL made up 0.03% of Royal London Asset Management's portfolio in Q4 2014, its #452 holding.
346 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q4 2014.

Based on Royal London Asset Management's 13F filing for Q4 2014, filed 11 Feb 2015.